We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Tumors Grow When Normal Cells Are Induced to Become Cancerous

By LabMedica International staff writers
Posted on 13 Dec 2015
A recent study determined how the cancer cells within a tumor promote its growth by transforming neighboring normal epithelial cells into cancer cells.

In epithelial cancers, carcinoma cells coexist with normal cells. More...
Although it was known that the tumor microenvironment played a pivotal role in cancer progression, it was not completely understood how the tumor influenced adjacent normal epithelial cells.

In a recent study, investigators at the University of Delaware (Newark, USA) employed a three-dimensional co-culture system comprising non-transformed epithelial cells (MDCK) and transformed carcinoma cells (MSV-MDCK) to demonstrate that carcinoma cells sequentially induced cancer-like changes, including preneoplastic lumen filling and epithelial–mesenchymal transition (EMT) in epithelial cysts.

The investigators found that at the molecular level, the protease MMP-9 (matrix metallopeptidase 9) secreted by carcinoma cells cleaved cellular E-cadherin from epithelial cells to generate soluble E-cadherin (sE-cad), a pro-oncogenic protein.

Cadherins are members of a family of calcium-dependent cell adhesion proteins that preferentially interact in a homophilic manner in cell-cell interactions. They are type I membrane proteins that contribute to the sorting of heterogeneous cell types. Typically, cadherins have five similar extracellular domains, the outermost three of which have Ca2+-binding sites, and an intracellular C-terminal domain that interacts with the actin cytoskeleton. Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.

In the current study, the investigators showed that sE-cad induced EGFR (epidermal growth factor receptor) activation, resulting in lumen filling in MDCK cysts, and that long-term sE-cad treatment induced EMT. Therefore, they were able to demonstrate that carcinoma cells could induce sE-cad shedding in adjacent epithelial cells, which led to EGFR activation and the eventual transdifferentiation of the normal epithelial cells.

Senior author Dr. Ayyappan Rajasekaran, adjunct professor of materials science and engineering at the University of Delaware, said, "This is the first time research has demonstrated that a cancer cell can sequentially induce early and late stages of cancer development in neighboring normal cells—a fundamental finding that can inform future studies. Like bacteria and viruses, cancer cells have the potential to infect normal cells and promote cancer progression. Future studies should give a new dimension to our understanding of cancer development and treatment."

Related Links:

University of Delaware



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.